Evelyn Partners Investment Management LLP Buys 1,667,652 Shares of Astrazeneca Plc $AZN

Evelyn Partners Investment Management LLP lifted its position in Astrazeneca Plc (NYSE:AZN) by 22,315.7% in the first quarter, Holdings Channel.com reports. The institutional investor owned 1,675,125 shares of the company’s stock after purchasing an additional 1,667,652 shares during the period. Astrazeneca makes up about 8.8% of Evelyn Partners Investment Management LLP’s holdings, making the stock its largest holding. Evelyn Partners Investment Management LLP’s holdings in Astrazeneca were worth $325,485,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. IHT Wealth Management LLC raised its holdings in Astrazeneca by 0.3% in the 4th quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock worth $3,076,000 after acquiring an additional 54 shares during the period. Visionary Wealth Advisors boosted its holdings in Astrazeneca by 1.5% during the fourth quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock valued at $737,000 after acquiring an additional 60 shares during the period. Vista Investment Management boosted its holdings in Astrazeneca by 0.3% during the fourth quarter. Vista Investment Management now owns 21,215 shares of the company’s stock valued at $3,723,000 after acquiring an additional 60 shares during the period. Kestra Investment Management LLC grew its position in shares of Astrazeneca by 1.9% in the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after purchasing an additional 63 shares during the last quarter. Finally, Luken Investment Analytics LLC increased its stake in shares of Astrazeneca by 4.3% in the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock worth $274,000 after purchasing an additional 64 shares during the period. 20.35% of the stock is owned by institutional investors.

Key Headlines Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Profit beat and outlook maintained: Second-quarter earnings were $2.63 per share, well above the $2.10 analyst consensus. AstraZeneca also backed its 2026 forecasts, helping ease concerns about longer-term growth. AstraZeneca beats second-quarter profit expectations, holds outlook
• Positive Sentiment: Oncology and rare-disease demand remained strong: Growth from cancer, heart-disease and rare-disease therapies helped offset weaker sales in other products and increasing generic competition. First-half revenue rose 9% to $30.7 billion, or 6% at constant exchange rates. AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
• Neutral Sentiment: Revenue slightly missed expectations: Quarterly revenue increased 6.4% year over year to $15.38 billion, narrowly below the $15.44 billion analyst estimate. Management is also navigating weaker conditions in China and the loss of exclusivity for certain products. AstraZeneca Q2 2026 Earnings Call Highlights
• Negative Sentiment: Pipeline setback: Ultomiris failed to meet the main goal in a late-stage trial involving a blood-vessel complication after stem-cell transplantation. The result adds to recent concerns about AstraZeneca’s development pipeline, although the company’s established portfolio supported the quarter. AstraZeneca’s rare disease drug misses main goal in late-stage trial
• Negative Sentiment: U.S. pricing pressure remains a risk: AstraZeneca is adjusting pricing strategies for new medicines in response to the Trump administration’s most-favoured-nation policy, which could constrain future pricing and margins in the U.S. AstraZeneca drug prices evolving in response to Trump policy

Astrazeneca Price Performance

Shares of AZN stock opened at $170.02 on Tuesday. The stock’s fifty day simple moving average is $180.27 and its 200 day simple moving average is $187.99. Astrazeneca Plc has a one year low of $142.98 and a one year high of $212.71. The firm has a market cap of $263.68 billion, a price-to-earnings ratio of 25.53, a P/E/G ratio of 1.38 and a beta of 0.24. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.13. The firm had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.17 earnings per share. On average, analysts expect that Astrazeneca Plc will post 10.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, Bank of America reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.